Genetic drug target validation using Mendelian randomisation.

Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, Tyl B, Chopade S, Faraway R, Zwierzyna M, Hingorani AD. · 2020

Read Genetic drug target validation using Mendelian randomisation. by Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, Tyl B, Chopade S, Faraway R, Zwierzyna M, Hingorani AD. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7320010.txt.

Description

Schmidt and co-authors sharpen a genetic method, Mendelian randomisation, for judging whether a protein is a good drug target. Their paper appeared in Nature Communications. The method uses genetic variants as natural instruments to test whether a risk factor truly causes disease. Its weak spot is horizontal pleiotropy, where a variant influences disease through a second, unrelated pathway.

When the risk factor is a protein, that worry shrinks. Proteins are the direct products of genes and the proximal effectors of biology, and most medicines target proteins. The authors build a mathematical framework contrasting protein targets with risk factors further down the causal chain. It guides key model decisions, boosts statistical power, and tests how robust a target-validation result really is before money is spent on drug development.

Catalog record

CREATORSchmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, Tyl B, Chopade S, Faraway R, Zwierzyna M, Hingorani AD.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE74 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7320010

Browse the full library · About the Tower of Babel